BACKGROUND: Insulin-like growth factor-I (IGF-I) is a potent mitogen. IGF-I and its main binding protein, IGF binding protein-3 (IGFBP-3), and their polymorphisms have been investigated in relation to risk of many cancers, but not esophageal adenocarcinoma. MATERIALS AND METHODS: We used data and specimens from a longitudinal study of persons with Barrett's esophagus (n=344; median, 5.4 years follow up) to determine whether baseline serum concentrations of IGF-I and IGFBP-3 and associated polymorphisms were related to the risk of developing esophageal adenocarcinoma or flow cytometric abnormalities. RESULTS: Overall, circulating concentrations of IGF-I and IGBP-3 were not associated with risk of esophageal adenocarcinoma or flow cytometric abnormalities, with the exception of an approximate tripling of risk of aneuploidy among participants with higher IGFBP-3 levels [above median; adjusted hazard ratio (HR) comparing subjects with levels lower than median versus higher of equal to median, 2.7; 95% confidence interval (95% CI), 1.2-6.0; P=0.01]. Genotypic analyses revealed that persons with the IGF-I [cytosine-adenine (CA)](19) or the IGFBP-3 A-202C C allele were associated with lower circulating concentrations of IGF-I (P(trend)=0.01) and IGFBP-3 (P(trend)=0.002), respectively. Persons with two copies of the IGF-I receptors 2-bp deletion allele had a nonsignificant 2-fold increased risk of tetraploidy (HR, 2.3; 95% CI, 0.9-5.9; P(trend)=0.11). After adjustment for IGFBP-3 levels, participants carrying two IGFBP-3 C alleles had a significantly higher risk of developing aneuploidy (HR, 3.8; 95% CI, 1.0-14.0; P(trend)=0.04) than carriers of A alleles; whereas no associations were observed between the outcomes studied and the IGF-I receptors AGG trinucleotide repeat polymorphism at position 97. CONCLUSION: Our findings, although based on a relatively small number of outcomes and subject to several limitations, indicate a potential role of the complex IGF system in neoplastic progression among persons with Barrett's esophagus.
BACKGROUND:Insulin-like growth factor-I (IGF-I) is a potent mitogen. IGF-I and its main binding protein, IGF binding protein-3 (IGFBP-3), and their polymorphisms have been investigated in relation to risk of many cancers, but not esophageal adenocarcinoma. MATERIALS AND METHODS: We used data and specimens from a longitudinal study of persons with Barrett's esophagus (n=344; median, 5.4 years follow up) to determine whether baseline serum concentrations of IGF-I and IGFBP-3 and associated polymorphisms were related to the risk of developing esophageal adenocarcinoma or flow cytometric abnormalities. RESULTS: Overall, circulating concentrations of IGF-I and IGBP-3 were not associated with risk of esophageal adenocarcinoma or flow cytometric abnormalities, with the exception of an approximate tripling of risk of aneuploidy among participants with higher IGFBP-3 levels [above median; adjusted hazard ratio (HR) comparing subjects with levels lower than median versus higher of equal to median, 2.7; 95% confidence interval (95% CI), 1.2-6.0; P=0.01]. Genotypic analyses revealed that persons with the IGF-I [cytosine-adenine (CA)](19) or the IGFBP-3A-202C C allele were associated with lower circulating concentrations of IGF-I (P(trend)=0.01) and IGFBP-3 (P(trend)=0.002), respectively. Persons with two copies of the IGF-I receptors 2-bp deletion allele had a nonsignificant 2-fold increased risk of tetraploidy (HR, 2.3; 95% CI, 0.9-5.9; P(trend)=0.11). After adjustment for IGFBP-3 levels, participants carrying two IGFBP-3 C alleles had a significantly higher risk of developing aneuploidy (HR, 3.8; 95% CI, 1.0-14.0; P(trend)=0.04) than carriers of A alleles; whereas no associations were observed between the outcomes studied and the IGF-I receptors AGG trinucleotide repeat polymorphism at position 97. CONCLUSION: Our findings, although based on a relatively small number of outcomes and subject to several limitations, indicate a potential role of the complex IGF system in neoplastic progression among persons with Barrett's esophagus.
Authors: Katarina B Greer; Cheryl L Thompson; Lacie Brenner; Beth Bednarchik; Dawn Dawson; Joseph Willis; William M Grady; Gary W Falk; Gregory S Cooper; Li Li; Amitabh Chak Journal: Gut Date: 2011-09-19 Impact factor: 23.059
Authors: Yi-An Ko; Bhramar Mukherjee; Jennifer A Smith; Sharon L R Kardia; Matthew Allison; Ana V Diez Roux Journal: Epidemiology Date: 2016-11 Impact factor: 4.822
Authors: José O Alemán; Peter R Holt; Leonardo H Eusebi; Luigi Ricciardiello; Kavish Patidar; Arun J Sanyal Journal: Gastroenterology Date: 2013-12-06 Impact factor: 22.682
Authors: Yumie Takata; Irena B King; Johanna W Lampe; Raymond F Burk; Kristina E Hill; Regina M Santella; Alan R Kristal; David J Duggan; Thomas L Vaughan; Ulrike Peters Journal: J Nutr Date: 2012-01-18 Impact factor: 4.798
Authors: Shruti G Dighe; Jianhong Chen; Li Yan; Qianchuan He; Puya Gharahkhani; Lynn Onstad; David M Levine; Claire Palles; Weimin Ye; Marilie D Gammon; Prasad G Iyer; Lesley A Anderson; Geoffrey Liu; Anna H Wu; James Y Dai; Wong-Ho Chow; Harvey A Risch; Jesper Lagergren; Nicholas J Shaheen; Leslie Bernstein; Douglas A Corley; Hans Prenen; John deCaestecker; David MacDonald; Paul Moayyedi; Hugh Barr; Sharon B Love; Laura Chegwidden; Stephen Attwood; Peter Watson; Rebecca Harrison; Katja Ott; Susanne Moebus; Marino Venerito; Hauke Lang; Rupert Mayershofer; Michael Knapp; Lothar Veits; Christian Gerges; Josef Weismüller; Ines Gockel; Yogesh Vashist; Markus M Nöthen; Jakob R Izbicki; Hendrik Manner; Horst Neuhaus; Thomas Rösch; Anne C Böhmer; Arnulf H Hölscher; Mario Anders; Oliver Pech; Brigitte Schumacher; Claudia Schmidt; Thomas Schmidt; Tania Noder; Dietmar Lorenz; Michael Vieth; Andrea May; Timo Hess; Nicole Kreuser; Jessica Becker; Christian Ell; Christine B Ambrosone; Kirsten B Moysich; Stuart MacGregor; Ian Tomlinson; David C Whiteman; Janusz Jankowski; Johannes Schumacher; Thomas L Vaughan; Margaret M Madeleine; Laura J Hardie; Matthew F Buas Journal: Carcinogenesis Date: 2021-04-17 Impact factor: 4.944